CN1596304A - 蛋白质结节 - Google Patents
蛋白质结节 Download PDFInfo
- Publication number
- CN1596304A CN1596304A CNA02822101XA CN02822101A CN1596304A CN 1596304 A CN1596304 A CN 1596304A CN A02822101X A CNA02822101X A CN A02822101XA CN 02822101 A CN02822101 A CN 02822101A CN 1596304 A CN1596304 A CN 1596304A
- Authority
- CN
- China
- Prior art keywords
- cys
- pro
- ser
- thr
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 288
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 286
- 235000018102 proteins Nutrition 0.000 claims abstract description 278
- 238000000034 method Methods 0.000 claims abstract description 80
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 31
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 932
- 230000003993 interaction Effects 0.000 claims description 41
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 36
- 108091005804 Peptidases Proteins 0.000 claims description 21
- 102000035195 Peptidases Human genes 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000001742 protein purification Methods 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 2
- 230000008676 import Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract description 3
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 420
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 394
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 363
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 328
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 260
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 237
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 215
- 239000000370 acceptor Substances 0.000 description 77
- 210000004899 c-terminal region Anatomy 0.000 description 76
- 239000000833 heterodimer Substances 0.000 description 65
- 102220023257 rs387907546 Human genes 0.000 description 65
- 230000000694 effects Effects 0.000 description 57
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 42
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 42
- 102220004457 rs11567847 Human genes 0.000 description 42
- 239000005556 hormone Substances 0.000 description 39
- 229940088597 hormone Drugs 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 34
- 239000000523 sample Substances 0.000 description 31
- 102220369445 c.668T>C Human genes 0.000 description 25
- 108010060374 FSH Receptors Proteins 0.000 description 24
- 102000008175 FSH Receptors Human genes 0.000 description 24
- 230000008859 change Effects 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 238000011160 research Methods 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 230000027455 binding Effects 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- 229920001542 oligosaccharide Polymers 0.000 description 12
- 150000002482 oligosaccharides Chemical class 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 102220369447 c.1352G>A Human genes 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 210000001685 thyroid gland Anatomy 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 238000005336 cracking Methods 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 7
- 241000699802 Cricetulus griseus Species 0.000 description 6
- 108090000204 Dipeptidase 1 Proteins 0.000 description 6
- 102000006635 beta-lactamase Human genes 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 102220023258 rs387907548 Human genes 0.000 description 6
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 5
- 102000023108 LH Receptors Human genes 0.000 description 5
- 108010011942 LH Receptors Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000012219 cassette mutagenesis Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 108700012941 GNRH1 Proteins 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 102220369446 c.1274G>A Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 102200067148 rs769650474 Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101001038874 Homo sapiens Glycoprotein hormones alpha chain Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000006035 Tryptophane Substances 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 108091008039 hormone receptors Proteins 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 102220001770 rs137852957 Human genes 0.000 description 3
- 102220005413 rs33911106 Human genes 0.000 description 3
- 102200075809 rs587777231 Human genes 0.000 description 3
- 230000007781 signaling event Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 102000003916 Arrestin Human genes 0.000 description 2
- 108090000328 Arrestin Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 2
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 2
- 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 description 2
- 230000010740 Hormone Receptor Interactions Effects 0.000 description 2
- 102220476515 Interleukin-18_K44A_mutation Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000011243 crosslinked material Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 2
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 102220234445 rs1064796078 Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 description 1
- 102220547856 Apoptosis-associated speck-like protein containing a CARD_M47Q_mutation Human genes 0.000 description 1
- 239000004475 Arginine Chemical group 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102220519085 Cytochrome P450 1A2_S18C_mutation Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- OCYROESYHWUPBP-CIUDSAMLSA-N Pro-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 OCYROESYHWUPBP-CIUDSAMLSA-N 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102220465722 Serine/threonine-protein kinase ULK3_K44R_mutation Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 102220349282 c.275C>G Human genes 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011062 flow through chromatography Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010026195 glycanase Proteins 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 102000045729 human CGA Human genes 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 238000003257 protein preparation method Methods 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102200071102 rs104894884 Human genes 0.000 description 1
- 102200004838 rs886041001 Human genes 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34528301P | 2001-11-08 | 2001-11-08 | |
| US60/345,283 | 2001-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1596304A true CN1596304A (zh) | 2005-03-16 |
Family
ID=23354368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA02822101XA Pending CN1596304A (zh) | 2001-11-08 | 2002-11-08 | 蛋白质结节 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1497634A4 (es) |
| JP (2) | JP2005509652A (es) |
| KR (1) | KR20040063928A (es) |
| CN (1) | CN1596304A (es) |
| CA (1) | CA2466595A1 (es) |
| EA (1) | EA200400647A1 (es) |
| HR (1) | HRP20040242A2 (es) |
| IL (1) | IL161804A0 (es) |
| MX (1) | MXPA04004289A (es) |
| NO (1) | NO20042358L (es) |
| PL (1) | PL373566A1 (es) |
| WO (1) | WO2003040695A2 (es) |
| ZA (1) | ZA200404373B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1769000B1 (en) * | 2004-07-16 | 2014-12-24 | Amgen Research (Munich) GmbH | Expression-enhanced polypeptides |
| GB201403815D0 (en) * | 2014-03-04 | 2014-04-16 | Mologic Ltd | Assay |
| CN112986571B (zh) * | 2019-12-12 | 2023-04-11 | 中国科学院大连化学物理研究所 | 一种鉴定Midkine时空网络相互作用蛋白质的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE190461T1 (de) * | 1983-11-02 | 2000-04-15 | Applied Research Systems | Produkte und methoden für die herstellung einer heterodimerer menschlicher lh mit einem met42 val55 alpha untereinheit |
| DK0461200T3 (da) * | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| WO1997004080A1 (fr) * | 1995-07-14 | 1997-02-06 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Nouvelle proteine et anticorps monoclonal specifique a cette derniere |
| US6001354A (en) * | 1995-11-17 | 1999-12-14 | Washington University | GRB2 associating polypeptides and nucleic acids encoding therefor |
| US5837837A (en) * | 1997-02-27 | 1998-11-17 | Millennium Pharmaceuticals, Inc. | Nucleic acids molecules encoding Caspase-8h and Caspase-8i |
| DK1775346T3 (da) * | 1997-06-25 | 2009-09-28 | Merck Serono Sa | Disulfid-tværbundne glycoproteinhormonanaloger, deres fremstilling og anvendelse |
-
2002
- 2002-11-08 CN CNA02822101XA patent/CN1596304A/zh active Pending
- 2002-11-08 EA EA200400647A patent/EA200400647A1/ru unknown
- 2002-11-08 PL PL02373566A patent/PL373566A1/xx not_active Application Discontinuation
- 2002-11-08 JP JP2003542901A patent/JP2005509652A/ja active Pending
- 2002-11-08 CA CA002466595A patent/CA2466595A1/en not_active Abandoned
- 2002-11-08 MX MXPA04004289A patent/MXPA04004289A/es not_active Application Discontinuation
- 2002-11-08 EP EP02789525A patent/EP1497634A4/en not_active Withdrawn
- 2002-11-08 KR KR10-2004-7006994A patent/KR20040063928A/ko not_active Application Discontinuation
- 2002-11-08 IL IL16180402A patent/IL161804A0/xx unknown
- 2002-11-08 WO PCT/US2002/035914 patent/WO2003040695A2/en active Application Filing
-
2004
- 2004-03-12 HR HR20040242A patent/HRP20040242A2/hr not_active Application Discontinuation
- 2004-06-03 ZA ZA2004/04373A patent/ZA200404373B/en unknown
- 2004-06-07 NO NO20042358A patent/NO20042358L/no not_active Application Discontinuation
-
2007
- 2007-10-11 JP JP2007265961A patent/JP2008110973A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040242A2 (en) | 2005-02-28 |
| JP2005509652A (ja) | 2005-04-14 |
| ZA200404373B (en) | 2005-11-30 |
| WO2003040695A2 (en) | 2003-05-15 |
| JP2008110973A (ja) | 2008-05-15 |
| WO2003040695A3 (en) | 2004-11-11 |
| CA2466595A1 (en) | 2003-05-15 |
| NO20042358L (no) | 2004-08-09 |
| MXPA04004289A (es) | 2005-03-31 |
| KR20040063928A (ko) | 2004-07-14 |
| PL373566A1 (en) | 2005-09-05 |
| EA200400647A1 (ru) | 2004-10-28 |
| EP1497634A4 (en) | 2007-02-07 |
| EP1497634A2 (en) | 2005-01-19 |
| IL161804A0 (en) | 2005-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1305897C (zh) | 新肽化合物和其制备方法及含有它们的药物组合物 | |
| CN1310945C (zh) | 人g蛋白偶联受体的内源形式和非内源形式 | |
| CN1183158C (zh) | Exendin类似物,其制备方法及含有它们的药物制剂 | |
| CN1902226A (zh) | 单链胰岛素 | |
| CN1159341C (zh) | 治疗由皮质甾类诱发的骨质减少的方法 | |
| CN1068501A (zh) | A-c-b胰岛素原，其生产方法和应用，以及胰岛素生产中的中间体 | |
| CN1197968C (zh) | 二硫键交联的糖蛋白激素类似物及其制备和应用 | |
| CN1293096C (zh) | 合成甲状旁腺素类似物和甲状旁腺素相关肽的方法 | |
| CN1531545A (zh) | 降低融合蛋白的免疫原性 | |
| CN1678740A (zh) | 抗存在于血液中的gpc3的分泌性n－端肽或c－端肽的抗体 | |
| CN1671423A (zh) | 新型嵌合cd154 | |
| CN1756763A (zh) | 二聚体化肽 | |
| CN1968962A (zh) | 新型可溶性cd14抗原 | |
| CN1419563A (zh) | 肽衍生物 | |
| CN1261579C (zh) | 形成异源二聚体的杂种蛋白质 | |
| CN1140536C (zh) | 人血小板糖蛋白Ib/Ix的米摩托培和抗米摩托培 | |
| CN1158303C (zh) | 去除n-末端蛋氨酸的方法 | |
| CN1303299A (zh) | 关于肽合成的方法以及组合物 | |
| CN1155402C (zh) | 一种抑制信号－传导蛋白和glgf(pdz/d hr)区域之间相互作用的化合物及其应用 | |
| CN1328568A (zh) | 肽衍生物 | |
| CN1344321A (zh) | 筛选方法 | |
| CN1592793A (zh) | 肝细胞癌－相关基因和多肽,以及检测肝细胞癌的方法 | |
| CN1549858A (zh) | 内源和非内源型人g蛋白偶联受体 | |
| CN1509336A (zh) | 肽的制备方法 | |
| CN1170933C (zh) | 促胃动素同系物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: APPLIED RESEARCH SYSTEMS ARS HOLDINGS CO., LTD. Free format text: FORMER OWNER: MOYLE WILLIAM R. Effective date: 20051125 Owner name: MOYLE WILLIAM R. Free format text: FORMER OWNER: MOYLE WILLIAM R.; APPLICANT Effective date: 20051125 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20051125 Address after: Holland, Netherlands Antilles Applicant after: APPLIC RES SYSTEM ARS HOLDING Address before: New jersey, USA Applicant before: Moyle William R. Effective date of registration: 20051125 Address after: New jersey, USA Applicant after: Moyle William R. Address before: New jersey, USA Applicant before: Moyle William R. Co-applicant before: Xing Yongna |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1075917 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1075917 Country of ref document: HK |